Compare iShares MSCI Japan ETF (EWJ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Japan ETF trades at $97.88 (market cap $23.87B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: iShares MSCI Japan ETF is far larger — about 2.9× TG Therapeutics Inc's market cap, and iShares MSCI Japan ETF is more actively traded (5,412,820 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and TG Therapeutics Inc for 16 Days on average.
| EWJ | TGTX | |
|---|---|---|
Market Cap | $23.87B | $8.16B |
Volume | 5,412,820 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $59.06 |
52-Week Low | $78.36 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.76, down 0.57% on the day amid mixed technical signals with a neutral overall rating. The ETF faces headwinds from Japan's monetary policy uncertainty as the Bank of Japan continues its tightening cycle, while benefiting from international equity outperformance trends in 2026. Technical indicators show the ETF trading near pivot point resistance at $98 with support at $97.
The outlook remains balanced with potential upside from Japan's AI and semiconductor exposure offset by currency volatility and rising bond yields. Key risks include yen fluctuations and global rate pressures, while institutional interest in Japanese equities provides support. The ETF's performance will hinge on BOJ policy effectiveness and sustained international market strength.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
